Intellectual capital in the life sciences
The most conventional model for commercialising intellectual property in the life sciences sector is licensing or cross-licensing. We have experience with critical commercial issues such as:
- appropriate licensed fields, performance obligations, bases for calculating royalties, industry-typical and product specific royalty rates;
- milestone payments – both for development, product launch and post-launch;
- provisions addressing compounding royalties (“anti-stacking”); and
- steps to mitigate against the insolvency of the counter-party - a critical issue in the current environment.